Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing

Policy Number: AHS – G2060 – Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing	Prior Policy Name and Number, as applicable: • AHS – G2060 – Fecal Analysis in the Diagnosis of Intestinal Dysbiosis
Initial Presentation Date: 06/01/2021 Revision Date: N/A	

I.   Policy Description

Intestinal dysbiosis is defined as a disruption or imbalance of the intestinal microbial ecology (Guinane & Cotter, 2013). Dysbiosis is associated with many diseases, including irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), obesity, allergy, and diabetes (Carding, Verbeke, Vipond, Corfe, & Owen, 2015).

II.   Related Policies

Policy Number	Policy Title
AHS-G2056	Diagnosis of Idiopathic Environmental Intolerance
AHS-G2061	Fecal Calprotectin Testing
AHS-G2121	Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease

III.   Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Medical Policy Statements do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. If there is a conflict between this Policy and any relevant, applicable government policy [e.g. National Coverage Determinations (NCDs) for Medicare] for a particular member, then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage,

please visit their search website http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp& or the manual website

1. Fecal analysis by culture prior to fecal microbiota transplant (FMT) for the following microorganisms **MEETS COVERAGE CRITERIA**

    a. Extended spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae*

    b. Vancomycin-resistant *Enterococci* (VRE)

    c. Carbapenem-resistant *Enterobacteriaceae* (CRE)

    d. Methicillin-resistant *Staphylococcus aureus* (MRSA)

    e. *Campylobacter*

    f. *Shigella*

    g. *Salmonella*

2. Fecal analysis by nucleic acid amplification testing (NAAT) prior to fecal microbiota transplant (FMT) for the following microorganisms **MEETS COVERAGE CRITERIA.** a. *C. Difficile*

    b. *Campylobacter*

    c. *Salmonella*

    d. *Shigella*

    e. Shiga toxin-producing *Escherichia coli*

    f. Norovirus

    g. Rotavirus

    h. COVID-19 (SARS-CoV-2)

3. Fecal analysis by nucleic acid amplification testing (NAAT) prior to fecal microbiota transplant (FMT) for the following microorganisms **DOES NOT MEET COVERAGE CRITERIA**:

    a. Extended spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae*

    b. Vancomycin-resistant *Enterococci* (VRE)

c. Carbapenem-resistant *Enterobacteriaceae* (CRE)

d. Methicillin-resistant *Staphylococcus aureus* (MRSA)

e. Any other microorganisms not listed above

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of a patient's illness.

4. Fecal analysis of the following components **DOES NOT MEET COVERAGE CRITERIA** as a diagnostic test for the evaluation of intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal overgrowth of bacteria:

a. Triglycerides

b. Chymotrypsin
c. Iso-butyrate, iso-valerate, and n-valerate

d. Meat and vegetable fibers

e. Long chain fatty acids

f. Cholesterol

g. Total short chain fatty acids

h. Levels of *Lactobacilli*, bifidobacteria, and *E. coli* and other "potential pathogens," including *Aeromona*, *Bacillus cereus*, *Campylobacter*, *Citrobacter*, *Klebsiella*, *Proteus*, *Pseudomonas*, *Salmonella*, *Shigella*, *S. aureus*, *Vibrio*

i. Identification and quantitation of fecal yeast (including *C. albicans*, *C. tropicalis*, *Rhodoptorul* and *Geotrichum*)

j. N-butyrate

k. Beta-glucoronidase

l. pH

m. Short chain fatty acid distribution (adequate amount and proportions of the different short chain fatty acids reflect the basic status of intestinal metabolism)

n. Fecal secretory IgA

IV. Scientific Background

The human intestinal tract has a diverse and complex microbial community necessary for health and nutrition. The gut microbiome is estimated to consist of upwards of 1000 bacterial species (Guinane & Cotter, 2013; Ley, Peterson, & Gordon, 2006; Qin et al., 2010). The microbiota functions with the immune system to protect against pathogens. It also performs essential metabolic functions, extracting certain forms of energy and nutrients from food and providing a source of other essential nutrients and vitamins (Carding et al., 2015).

The gut is colonized at birth, but the intestinal microbiome changes rapidly during the first year of life. In adults, each individual's unique population of gut microbiota is fairly stable over time; however, alterations in the microbiota can result from exposure to various environmental factors, including diet, toxins, drugs, and pathogens (Carding et al., 2015; Lozupone, Stombaugh, Gordon, Jansson, & Knight, 2012; Snapper & Abraham, 2020). This change in an individual's normal microbiota is called "dysbiosis" (Johnston, 2020). Dysbiosis has been associated with obesity (Ley, Turnbaugh, Klein, & Gordon, 2006; Zhang et al., 2009) malnutrition (Kau, Ahern, Griffin, Goodman, & Gordon, 2011), systematic diseases such as diabetes (Qin et al., 2012) and chronic inflammatory diseases such as inflammatory bowel disease (IBD) (Frank et al., 2007; Guinane & Cotter, 2013). Both direct assessment of the gut microbiota (examination of bacteria levels) and indirect assessment (measurement of nonliving markers such as pH or beta-glucoronidase) have been proposed for investigation of intestinal dysbiosis.

Microbial or microbial-derived components have also been cited as potential representations of dysbiosis. For example, short-chain fatty acids have been identified as a mechanism to regulate intestinal processes and, as such, may represent dysbiosis (Johnston, 2020). These fatty acids are the products of bacterial fermentation of fiber, and the concentrations of these fatty acids have been noted to decrease in IBD cases. Some fatty acids, especially butyrate, have been demonstrated to factor in signaling cascades that control immune function, which indicates a role in controlling intestinal inflammation (Parada Venegas et al., 2019). Ongoing research has uncovered many other potential links between intestinal metabolism and gut microbiota so many markers have been suggested as potential indicators of dysbiosis.

Many tests exist for the assessment of the gut microbiome. Due to the amount of conditions associated (or proposed to be associated) with gut microbiome balance, there are many corresponding tests, including screening measures intended for completely healthy individuals. These tests primarily revolve around nucleic acid amplification; microbial DNA or RNA is obtained from the sample, unique sequences are identified, and the nucleic acid is quantified (Raby, 2020). For instance, Viome offers a comprehensive screening panel that measures "all microorganisms" in the gut (including viruses, archaea, yeast, fungi, parasites, and bacteriophages). Those measurements are combined into a score for various issues, such as inflammatory activity, digestive efficiency, methane gas production, overall gas production, and more (Viome, 2019a). Viome also provides a list of nutritional recommendations, broken down into individual foods. Viome performs RNA sequencing with Illumina NextSeq and uses bioinformatics algorithms to classify taxonomic data (Viome, 2019b).

Some companies may offer companion products with their gut microbiome tests. BioHM provides a similar assessment of bacterial and fungal species in an individual's gastrointestinal tract, but the company also offers a series of probiotics. These probiotics are intended for various purposes, such

as colon cleansing or immunity (BioHM, 2018). Other companies offering a gut microbiome test include Thryve, GenCove, DayTwo, American Gut, and Genova (DNATestingChoice, 2019; Genova, 2019).

The potential clinical impact of imbalance in the intestinal microbiota suggests a need for standardized diagnostic methods to facilitate microbiome profiling. Documenting dysbiosis has traditionally relied on classical microbiological techniques and the ability to culture pure isolates for identification and classification; however, the ability to classify bacteria and archaea according to individual 16S rRNA sequences can now possibly provide a rapid and detailed means of profiling complex communities of microorganisms (Casen et al., 2015; Zoetendal, Akkermans, & De Vos, 1998). Laboratory analysis of various fecal biomarkers have also been proposed as a method of identifying individuals with intestinal dysbiosis and may be useful in providing insight into the role of intestinal health and disease, and the development of non-gastrointestinal conditions associated with intestinal dysbiosis. However, there is a current lack of literature on the normal ranges of these biomarkers, which limit the applicability of these analyses in a general clinical setting (Bäckhed et al., 2012; Berry & Reinisch, 2013; Pang, Leach, Katz, Day, & Ooi, 2014).

A technique revolving around restoring balance in a patient's microbiome is fecal microbiota transplantation (FMT). FMT is the infusion of stool from a healthy donor to a patient with presumed gut dysbiosis. The concept behind this technique is that the healthy donor's stool can facilitate a restoration of the ill patient's gut microbiome. This technique has seen some significant success in the treatment of *C. difficile* infections and may have potential applications in some other gastrointestinal or metabolic conditions such as IBD or IBS. As with any transplant procedure, there are several screening procedures that must be undertaken to minimize risk of infection or other disease transmission. These screening procedures include evaluation of donor history, serum testing, and stool testing. The pathogens screened for in the donor's stool sample may vary between institutions, although some pathogens are universally screened for (such as enteric pathogens). (Kim & Gluck, 2019)

Falony et al. (2016) analyzed "two independent, extensively phenotyped cohorts: the Belgian Flemish Gut Flora Project (FGFP; discovery cohort; N = 1106) and the Dutch LifeLines-DEEP study (LLDeep; replication; N = 1135)." These two sets were integrated with global data sets, combining to yield 3948 items. A "core" set of 14 genera was identified. 69 clinical and questionnaire-based covariates were found to be associated with microbiota compositional variation with a 92% replication rate. The authors noted that "stool consistency showed the largest effect size, whereas medication explained largest total variance and interacted with other covariate-microbiota associations, but early-life events such as birth mode were not reflected in adult microbiota composition" (Falony et al., 2016)

Zhernakova et al. (2016) sequenced the gut microbiomes of 1,135 participants from a Dutch population-based cohort. The authors identified relations between the microbiome and "126 exogenous and intrinsic host factors, including 31 intrinsic factors, 12 diseases, 19 drug groups, 4 smoking categories, and 60 dietary factors." "Significant" associations were found between the gut microbiome and various intrinsic, environmental, dietary, medication parameters, and disease phenotypes. The authors calculated that 18.7% of variation in microbial composition could be explained by these factors, and they observed that fecal chromogranin A was exclusively associated with 61 microbial species, totaling 53% of the microbial composition. A more diverse microbiome was associated with low CgA concentrations. The authors concluded that "these results are an important

step toward a better understanding of environment-diet-microbe-host interactions" (Zhernakova et al., 2016).

Lo Presti et al. (2019) profiled the fecal and mucosal microbiota of IBD and IBS patients. 38 IBD patients, 44 IBS patients, and 47 healthy controls were included, and overall, 107 fecal samples were provided. The authors found that "*Anaerostipes* and *Ruminococcaceae* were identified as the most differentially abundant bacterial taxa in controls, *Erysipelotrichi* was identified as [a] potential biomarker for IBS, while *Gammaproteobacteria*, *Enterococcus*, and *Enterococcaceae* [were identified] for IBD" (Lo Presti et al., 2019).

Malham et al. (2019) investigated the microbiotic profile of pediatric IBD. 143 IBD patients and 34 healthy controls were included. A reduced "richness" in microbiotic profile was observed in IBD patients compared to healthy controls. In ulcerative colitis (UC), that reduced richness was associated with high intestinal inflammation and extensive disease. Nine species were "significantly" associated with a healthy microbiome, and three species were associated with IBD. The authors remarked that the microbiome composition could differentiate between Crohn's Disease, UC, and healthy controls (Malham et al., 2019).

Danilova et al. (2019) compared the gut microbiome composition of IBD patients to healthy controls. 95 IBD patients and 96 healthy controls were included. The authors noted an increase of Proteobacteria and Bacteroidetes bacteria and decrease of Firmicutes bacteria and Euryarchaeota archaea in IBD patients. Butyrate-producing and hydrogen-utilizing bacteria were observed to have lower representation in IBD patients. Short-chain fatty acids (SCFA) were also found to have a lower absolute content in IBD patients. The authors suggested that this finding may "indicate inhibition of functional activity and number of anaerobic microflora and/or an [*sic*] change in SCFA utilization by colonocytes" (Danilova et al., 2019).

Vaughn et al. (2018) in reviewing the current status of intestinal dysbiosis and fecal transplantation found that "it is hypothesized that intestinal dysbiosis may contribute to the pathogenesis of many diseases, especially those involving the gastrointestinal tract. Therefore, fecal microbiota transplantation (FMT) is increasingly being explored as a potential treatment that aims to optimize microbiota composition and functionality (Vaughn, Rank, & Khoruts, 2018)." Holleran et al also found that fecal transplant is not recommended for use outside of *Clostridium difficile* infection (CDI) due to concerns regarding outcome and safety; however, several case series and randomized controlled trials have described its use in a research environment for a few gastrointestinal conditions related to intestinal dysbiosis, including ulcerative colitis (UC), Crohn's disease (CD) and irritable bowel syndrome (IBS). The most successful reports of the clinical efficacy of FMT in gastrointestinal conditions outside of CDI have been in treating UC (Holleran et al., 2018).

Costello et al. (2019) evaluated fecal microbiota transplantation (FMT)'s efficacy on inducing remission in ulcerative colitis (UC). The authors compared anaerobically prepared donor FMT (n = 38) to autologous FMT (stool provided by patient themselves, n = 35). The primary outcome was defined as "steroid-free remission of UC... a total Mayo score of ≤2 with an endoscopic Mayo score of 1 or less at week 8." A total of 69 patients completed the trial, with the primary outcome being achieved in 12 of 38 donor FMT patients, compared to 3 of 35 receiving autologous FMT. Five of the 12 patients achieving the primary outcome in the "donor cohort" maintained remission at 12 months. The authors concluded that "in this preliminary study of adults with mild to moderate UC, 1-week treatment with

anaerobically prepared donor FMT compared with autologous FMT resulted in a higher likelihood of remission at 8 weeks. Further research is needed to assess longer-term maintenance of remission and safety" (Costello et al., 2019).

Myneedu et al. (2019) performed a meta-analysis to evaluate whether fecal microbiota transplantation (FMT) was successful in treating IBS. A total of 8 single-arm trials (SATs, 90 patients total) and 5 randomized controlled trials (RCTs, 151 patients, 105 controls) were included. In the SAT cohort, the authors identified 59.5% of IBS patients demonstrating a significant improvement. In the RCT cohort, there were no significant differences between treatment and control cohorts, either by the IBS Severity Scoring System or the IBS Quality of Life (IBS-QOL). The authors concluded that "FMT was not effective in IBS. Variations in FMT methods and patient factors may contribute to the heterogeneous results of the trials" (Myneedu, Deoker, Schmulson, & Bashashati, 2019).

V. Guidelines and Recommendations

World Gastroenterology Organization Global Guidelines (Bernstein et al., 2016; Hunt et al., 2014)

The WGO published guidelines on functional gastrointestinal (GI) symptoms. In it, they identify diagnostic tests for these symptoms. The basic diagnostic tests are as follows:

- Complete blood cell count (CBC)
- Erythrocyte sedimentation rate (ESR) / C-reactive protein (CRP)
- Biochemistry panel
- Fecal occult blood (patient aged > 50 y)
- Pregnancy test
- Liver function tests
- Calprotectin or other fecal test to detect inflammatory bowel disease in patients thought to have IBS, but in whom inflammatory bowel disease (IBD) is a possibility; now routine in many primary care settings (in the United Kingdom)
- Celiac serology; considered routine in areas with a high prevalence of celiac disease
- Stool testing for ova and parasites (Hunt et al., 2014)

The WGO also released their global guidelines for Inflammatory Bowel Disease in 2015 (published in 2016). Their recommendations concerning stool examination and testing are as follows:

- "Routine fecal examinations and cultures should be carried out to eliminate bacterial, viral, or parasitic causes of diarrhea."
- "Testing for *Clostridium difficile* (should be considered even in the absence of antecedent antibiotics) — should be carried out within 2 hours of passage of stools."
- "A check for occult blood or fecal leukocytes should be carried out if a patient presents without a history of blood in the stool, as this can strengthen the indication for lower endoscopy. Where lower endoscopy is readily available, these tests are rarely indicated."
- "Lactoferrin, α1-antitrypsin. The main reason for listing this test is to rule out intestinal inflammation, rather than using it as a positive diagnostic test. It may not be available in

developing countries, but it can be undertaken relatively inexpensively and easily with rapidturnaround slide-based enzyme-linked immunoassay (ELISA) tests."

- "Calprotectin — a simple, reliable, and readily available test for measuring IBD activity — may be better for UC than CD; the rapid fecal calprotectin tests could be very helpful in developing countries. If available, a home test may be useful as a routine for follow-up (Bernstein et al., 2016)."

American Gastroenterological Association (AGA) (Colombel, Shin, & Gibson, 2019)

The AGA published a review to "describe key principles in the diagnosis and management of functional gastrointestinal (GI) symptoms in patients with inflammatory bowel disease". In it, they include the following relevant items:

- "Alternative pathophysiologic mechanisms should be considered and evaluated (small intestinal bacterial overgrowth, bile acid diarrhea, carbohydrate intolerance, chronic pancreatitis) based on predominant symptom patterns."

- "Until further evidence is available, fecal microbiota transplant should not be offered for treatment of functional GI symptoms in IBD."

- "In a recent cross-sectional analysis, no association was observed between IBS symptoms and microbiome alterations among patients with IBD although effects of confounding could not be excluded." (Colombel et al., 2019)

American College of Gastroenterology (ACG) (Lichtenstein et al., 2018; Pimentel, Saad, Long, & Rao, 2020; Rubin, Ananthakrishnan, Siegel, Sauer, & Long, 2019)

The ACG published an update on SIBO (Small Intestinal Bacterial Overgrowth). This guideline addresses diagnostic testing and treatment options for SIBO. Their recommendations include:

- "We suggest the use of breath testing (glucose hydrogen or lactulose hydrogen) for the diagnosis of SIBO in patients with IBS (conditional recommendation, very low level of evidence)."

- "We suggest using glucose hydrogen or lactulose hydrogen breath testing for the diagnosis of SIBO in symptomatic patients with suspected motility disorders (conditional recommendation, very low level of evidence)."

- "We suggest testing for SIBO using glucose hydrogen or lactulose hydrogen breath testing in symptomatic patients (abdominal pain, gas, bloating, and/or diarrhea) with previous luminal abdominal surgery (conditional recommendation, very low level of evidence)."

- "We suggest testing for methane using glucose or lactulose breath tests to diagnose the overgrowth of methane-producing organisms (IMO) in symptomatic patients with constipation (conditional recommendation, very low level of evidence)."

The ACG also notes that although "Small bowel aspirate and culture is often considered the gold standard for the diagnosis of SIBO," there have been some preliminary studies focusing on use of nucleic acid testing to diagnose SIBO. However, the ACG remarks that "Large-scale studies are currently underway to evaluate this further."

The ACG also published a guideline regarding the management of Crohn's Disease. In it, they recommend that "In patients who have symptoms of active Crohn's disease, stool testing should be performed to include fecal pathogens, *Clostridium difficile* testing, and may include studies that identify gut inflammation such as a fecal calprotectin" (Lichtenstein et al., 2018).

The ACG published a guideline regarding management of ulcerative colitis. In it, the ACG writes that "FMT requires more study and clarification of treatment before use as a therapy for UC [ulcerative colitis]." The ACG comments that the variability across all steps of the procedure (donor screening, delivery, treatment duration, et al.) makes interpretation of the current results "difficult". Finally, the ACG notes that some institutions have been using "comprehensive intestinal pathogen testing through PCR-based assays that include many bacterial and viral pathogens," but that the "prevalence and impact of non–C. diff intestinal pathogens detected through such assays remain to be robustly established" (Rubin et al., 2019).

European Crohn's and Colitis Organization (ECCO) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) (Maaser et al., 2018)

These joint guidelines include some relevant items on inflammatory bowel disease (IBD), which includes both Crohn's disease (CD) and ulcerative colitis (UC). These items include:

- "At diagnosis, every patient should have a biochemical assessment with full blood count, inflammatory markers (C-reactive protein [CRP])... and a stool sample for microbiological analysis, including *C. difficile*."
- "Stool specimens should be obtained to exclude common pathogens and specifically assayed for C difficile toxin." (Maaser et al., 2018)

2012 Rome Foundation Report (Simren et al., 2013)

An international Working Group convened in 2012 "to provide clinical guidance on modulation of gut microbiota in IBS" and released their findings on intestinal microbiota in functional bowel disorders: a Rome foundation report in 2013. They state the following "Diagnostic and therapeutic general recommendations":

- "There is currently no clinically useful way of identifying whether the microbiota are disturbed in particular patients with irritable bowel syndrome (IBS).
- Dietary evaluation and exclusion of possible sources of unabsorbable carbohydrates including fermentable oligo-, di- and mono-saccharides and polyols and excessive fibre could be beneficial in select patients.
- Probiotics have a reasonable evidence base and should be tried, for a period of at least 1 month, at adequate doses before a judgement is made about the response to treatment.

- The utility of testing for small intestinal bacterial overgrowth (SIBO) in the setting of IBS remains an area of uncertainty.
- If SIBO is strongly suspected based on clinical presentation and testing is being considered, using stringent criteria for the glucose breath test or jejunal aspirate appear to be the best tests.
- Consideration should be given to discontinuing proton pump inhibitors in those with SIBO.
- There is emerging evidence that non-absorbable antibiotics may have the potential to reduce symptoms in some patients with IBS (Simren et al., 2013)."

European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases (ESPGHAN/ESPID)

These joint guidelines reviewed management of acute gastroenteritis (AGE) in children. In it, they note that AGE does not require a specific diagnostic workup and that "microbiological investigation is not helpful in most cases." Fecal markers are also not recommended for differentiating viral and bacterial AGE. However, the guidelines observe that "microbiological investigations may be considered in children with underlying chronic conditions (eg, oncologic diseases, IBDs, etc), in those in extremely severe conditions, or in those with prolonged symptoms in whom specific treatment is considered" (Guarino et al., 2014).

National Institute for Health and Care Excellence (NICE, 2017)

NICE updated their IBS guidelines in 2017. In it, they list the following items about diagnostic tests:

"In people who meet the IBS diagnostic criteria, the following tests should be undertaken to exclude other diagnoses:

- full blood count (FBC)
- erythrocyte sedimentation rate (ESR) or plasma viscosity
- c-reactive protein (CRP)
- antibody testing for coeliac disease (endomysial antibodies [EMA] or tissue transglutaminase [TTG]).

The following tests are not necessary to confirm diagnosis in people who meet the IBS diagnostic criteria:

- ultrasound
- rigid/flexible sigmoidoscopy
- colonoscopy; barium enema
- thyroid function test
- faecal ova and parasite test
- faecal occult blood
- hydrogen breath test (for lactose intolerance and bacterial overgrowth)" (NICE, 2017).

British Society of Gastroenterology (BSG) (Arasaradnam et al., 2018; Lamb et al., 2019)

The BSG published a guideline on the investigation of chronic diarrhoea in adults. Relevant items include:

- For malabsorption, fecal tests have not received "significant support" in publications and have not "established themselves in clinical practice outside specialist centres".
- "We suggest culture of small bowel aspirates as it is the most sensitive test for small bowel bacterial overgrowth (SBBO), but methods are poorly standardized and positive results may not reflect clinically significant SBBO… in the absence of an optimal test to confirm the presence of bacterial overgrowth and in those with a high test probability of SBBO, we recommend an empirical trial of antibiotics; the value of this approach has not been subject to definitive study."
- "We recommend faecal elastase testing as the preferred non-invasive test for pancreatic function" (Arasaradnam et al., 2018).

The BSG also published an extensive guideline on the management of Inflammatory Bowel Disease (including both ulcerative colitis (UC) and Crohn's disease) in adults. Their relevant comments and recommendations include:

- "In patients presenting with suspected UC, stool cultures and *Clostridium difficile* toxin assay should always be performed to rule out infective causes."
- "Ileocolonoscopy with biopsy is established as the first-line investigation for suspected Crohn's disease."
- "We recommend that all patients presenting with acute flares of colitis should have stool cultures for enteroinvasive bacterial infections and stool *Clostridium difficile* assay."
- "In spite of these encouraging data, FMT [Faecal microbial transplantation] remains an investigational treatment for use only in clinical trials in IBD."

- "There is currently no place for FMT in the management of IBD unless complicated by *C. difficile* infection outside of the clinical trial setting" (Lamb et al., 2019)

British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) (Mullish et al., 2018)

This joint guideline was published to provide guidance on "the use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications." These guidelines include a list of items that should be screened for potential stool donors, which are as follows:

- "*Clostridium difficile* PCR"

- "*Campylobacter*, *Salmonella*, and *Shigella* by standard stool culture and/ or PCR"

- "Shiga toxin-producing *Escherichia coli* by PCR"

- "Multi-drug resistant bacteria, at least CPE [*carbapenemase-producing Enterobacteriaceae*] and ESBL [extended spectrum beta-lactamase]"

- "Stool ova, cysts and parasite analysis, including for Microsporidia"

- "Faecal antigen for *Cryptosporidium* and *Giardia*"

- "Acid fast stain for *Cyclospora* and *Isospora*"

- "*Helicobacter pylori* faecal antigen"

- "Norovirus, rotavirus PCR."

The above list is for stool screening. A separate list is provided for serum screening. The guideline also recommends that "donors should have successfully completed a donor health questionnaire and laboratory screening assays both before and after the period of stool donation" (Mullish et al., 2018).

Infectious Diseases Society of America/American College of Gastroenterology/American Society for Gastrointestinal Endoscopy/American Gastroenterological Association/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (Davidovics et al., 2019; IDSA/ACG/ASGE/AGA/NASPGHAN, 2013; Michail, Nicholson, Kahn, & Kellermayer, 2020)

These joint guidelines were sent to the FDA regarding recurrent Clostridium difficile infection (CDI). In it, the guidelines recommend screening donors for fecal microbiota transplantation (FMT) for C. difficile toxin B and performing a culture for enteric pathogens (IDSA/ACG/ASGE/AGA/NASPGHAN, 2013).

NASPGHAN published an FMT guideline for children in 2019, and the same analytes for screening (C difficile toxin B, culture for enteric pathogens) were recommended (Davidovics et al., 2019).

An addendum was published to the 2019 guidelines due to the 2019 FDA Safety Warning regarding FMT. In it, the following recommendation was made: "FMT donor stool screening should include (but

not be limited to) MDRO testing for spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae*, vancomycin-resistant *Enterococci* (VRE), carbapenem-resistant *Enterobacteriaceae* (CRE), and methicillin-resistant *Staphylococcus aureus* (MRSA). Donors and/or stools positive for MDROs should not be used for FMT" (Michail et al., 2020).

Food and Drug Administration (FDA, 2019, 2020)

The FDA has issued a guidance statement for fecal microbiota transplant (FMT) stating that it will exercise enforcement discretion regarding the investigational new drug (IND) requirements for the use of fecal microbiota for transplantation. In 2019, the FDA updated their guidance on FMT, stating that "FMT donor stool testing must include MDRO testing to exclude use of stool that tests positive for MDRO. The MDRO tests should at minimum include extended spectrum beta-lactamase (ESBL)producing Enterobacteriaceae, vancomycin-resistant enterococci (VRE), carbapenem-resistant Enterobacteriaceae (CRE), and methicillin-resistant Staphylococcus aureus (MRSA). Culture of nasal or peri-rectal swabs is an acceptable alternative to stool testing for MRSA only. Bookend testing (no more than 60 days apart) before and after multiple stool donations is acceptable if stool samples are quarantined until the post-donation MDRO tests are confirmed negative (FDA, 2019)."

In an April 2020 update, the FDA addressed the topic of fecal microbiota transplantation within the context of the 2020 COVID-19 outbreak. The FDA included additional protections regarding stool donation and donor screening, which are as follows:

- "Stool donor screening, including an assessment of whether, since December 1, 2019, the donor was diagnosed with laboratory-confirmed SARS-CoV-2 infection, experienced symptoms of COVID-19 (e.g., fever, cough, shortness of breath) not explained by another diagnosis, or was exposed to a suspected or confirmed case of COVID-19 or SARS-CoV-2 infection."
- "Testing of the stool donation or stool donor for SARS-CoV-2 virus or RNA. Testing approaches might include testing upper respiratory specimens (e.g., nasal swabs) or other specimens (e.g., rectal swabs or stool donations)." (FDA, 2020)

Fecal Microbiota Transplantation Workgroup (2011)

This Working Group published guidelines on FMT. Fecal donor screening recommendations were included. The following analytes were recommended to be screened:

- "*C difficile* toxin B by PCR; if unavailable, then evaluation for toxins A and B by enzyme immunoassay (EIA)
- Routine bacterial culture for enteric pathogens
- Fecal Giardia antigen
- Fecal Cryptosporidium antigen
- Acid-fast stain for Cyclospora, Isospora, and, if antigen testing unavailable, Cryptosporidium
- Ova and parasites
- *Helicobacter pylori* fecal antigen (for upper gastrointestinal [GI] routes of FMT administration)" (Bakken et al., 2011).

American Gastroenterological Association (AGA, 2015)

The AGA published guidelines on FMT, including information on donor pathogen screening. *C. difficile* toxin B and culture for enteric pathogens were "suggested" to be screened for, *Giardia*, *Cryptosporidium*, *Isospora* and *Cyclospora*, *Listeria*, *E. coli* O157, *Vibrio*, and *Norovirus* should be "considered", and Cytomegalovirus, Human T-cell lymphoma virus, Epstein–Barr virus, *Dientamoeba fragilis*, *Blastocystis hominis*, *Strongyloides stercoralis*, *Entamoeba histolytica*, *H. pylori*, *Schistosoma*, JC virus, Vancomycin-resistant *enterococci*, and Methicillin-resistant *Staphylococcus aureus* should "maybe" [term used by authors] be screened (Kelly et al., 2015).

VI.   State and Federal Regulations, as applicable

Searches for "dysbiosis" and "microbiome" on the FDA website on August 6, 2020, yielded no results. Additionally, many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

VII.   Applicable CPT/HCPCS Procedure Codes

Billing applicable codes is not a guarantee of payment; see Section III for indications and limitations of coverage that may affect payment

CPT	Code Description
82239	Bile acids; total
82542	Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), nondrug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
82710	Fat or lipids, feces; quantitative
82715	Fat differential, feces, quantitative
82725	Fatty acids, nonesterified
82784	Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83630	Lactoferrin, fecal; qualitative
83986	pH; body fluid, not otherwise specified
84311	Spectrophotometry, analyte not elsewhere specified

87045	Culture, bacterial; stool, aerobic, with isolation and preliminary examination (eg, KIA, LIA), Salmonella and Shigella species
87046	Culture, bacterial; stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate
87075	Culture, bacterial; any source, except blood, anaerobic with isolation and presumptive identification of isolates
87102	Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; other source (except blood)
87177	Ova and parasites, direct smears, concentration and identification
87209	Smear, primary source with interpretation; complex special stain (eg, trichrome, iron hemotoxylin) for ova and parasites
87328	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzymelinked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; cryptosporidium
87329	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzymelinked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; giardia
87336	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzymelinked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Entamoeba histolytica dispar group
87493	Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique
87500	Infectious agent detection by nucleic acid (DNA or RNA); vancomycin resistance (eg, enterococcus species van A, van B), amplified probe technique

87641	Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified probe technique
87798	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism
89160	Meat fibers, feces

VIII. Evidence-based Scientific References

aradnam, R. P., Brown, S., Forbes, A., Fox, M. R., Hungin, P., Kelman, L., . . . Walters, J. R. F. (2018). Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. *Gut, 67*(8), 1380. doi:10.1136/gutjnl-2017-315909

Bäckhed, F., The Wallenberg Laboratory, U. o. G., Sahlgrenska University Hospital, Göteborg, Sweden 41345, Institute for Genome Sciences at the University of Maryland School of Medicine, B., MD 21201, USA, Ringel, Y., Division of Gastroenterology and Hepatology, D. o. M., University of North Carolina at Chapel Hill, NC 27599, USA, Dairy & Food Culture Technologies, C., CO 80122, USA, . . . bfinlay@msl.ubc.ca. (2012). Defining a Healthy Human Gut Microbiome: Current Concepts, Future Directions, and Clinical Applications. *Cell Host & Microbe, 12*(5), 611-622. doi:10.1016/j.chom.2012.10.012

Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., . . . Surawicz, C. (2011). Treating Clostridium Difficile Infection With Fecal Microbiota Transplantation. *Clinical Gastroenterology and Hepatology, 9*(12), 1044-1049. doi:10.1016/j.cgh.2011.08.014

Bernstein, C. N., Eliakim, A., Fedail, S., Fried, M., Gearry, R., Goh, K. L., . . . LeMair, A. (2016). World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. *J Clin Gastroenterol, 50*(10), 803-818. doi:10.1097/mcg.0000000000000660

Berry, D., & Reinisch, W. (2013). Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? *Best Pract Res Clin Gastroenterol, 27*(1), 47-58. doi:10.1016/j.bpg.2013.03.005

BioHM. (2018). Retrieved from https://biohmhealth.com/

Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M., & Owen, L. J. (2015). Dysbiosis of the gut microbiota in disease. *Microb Ecol Health Dis, 26*. doi:10.3402/mehd.v26.26191

Casen, C., Vebo, H. C., Sekelja, M., Hegge, F. T., Karlsson, M. K., Ciemniejewska, E., . . . Rudi, K. (2015). Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. *Aliment Pharmacol Ther, 42*(1), 71-83. doi:10.1111/apt.13236

Colombel, J. F., Shin, A., & Gibson, P. R. (2019). AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. *Clin Gastroenterol Hepatol, 17*(3), 380-390.e381. doi:10.1016/j.cgh.2018.08.001

Costello, S. P., Hughes, P. A., Waters, O., Bryant, R. V., Vincent, A. D., Blatchford, P., . . . Andrews, J. M. (2019). Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. *Jama, 321*(2), 156-164. doi:10.1001/jama.2018.20046

Danilova, N. A., Abdulkhakov, S. R., Grigoryeva, T. V., Markelova, M. I., Vasilyev, I. Y., Boulygina, E. A., . . . Abdulkhakov, R. A. (2019). Markers of dysbiosis in patients with ulcerative colitis and Crohn's disease. *Ter Arkh, 91*(4), 17-24. doi:10.26442/00403660.2019.04.000211

Davidovics, Z. H., Michail, S., Nicholson, M. R., Kociolek, L. K., Pai, N., Hansen, R., . . . Kellermayer, R.

(2019). Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr, 68*(1), 130-143. doi:10.1097/mpg.0000000000002205

DNATestingChoice. (2019). Microbiome Testing. Retrieved from https://dnatestingchoice.com/enus/microbiome-testing

Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., . . . Raes, J. (2016). Population-level analysis of gut microbiome variation. *Science, 352*(6285), 560-564. doi:10.1126/science.aad3503

FDA. (2019). Fecal Microbiota for Transplantation: Safety Communication- Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms. Retrieved from https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/fecalmicrobiota-transplantation-safety-communication-risk-serious-adverse-reactions-due

FDA. (2020). Fecal Microbiota for Transplantation: New Safety Information - Regarding Additional Protections for Screening Donors for COVID-19 and Exposure to SARS-CoV-2 and Testing for SARS-CoV-2. Retrieved from https://www.fda.gov/safety/medical-product-safetyinformation/fecal-microbiota-transplantation-new-safety-information-regarding-additionalprotections-screening

Frank, D. N., St Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007). Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A, 104*(34), 13780-13785. doi:10.1073/pnas.0706625104

Genova. (2019). Organix® Dysbiosis Profile. Retrieved from https://www.gdx.net/uk/product/organixdysbiosis-test-urine

Guarino, A., Ashkenazi, S., Gendrel, D., Lo Vecchio, A., Shamir, R., & Szajewska, H. (2014). European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe: Update 2014. *59*(1), 132-152. doi:10.1097/mpg.0000000000000375

Guinane, C. M., & Cotter, P. D. (2013). Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. *Therap Adv Gastroenterol, 6*(4), 295-308. doi:10.1177/1756283x13482996

Holleran, G., Scaldaferri, F., Ianiro, G., Lopetuso, L., Mc Namara, D., Mele, M. C., . . . Cammarota, G. (2018). Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: an update. *Drugs Today (Barc), 54*(2), 123-136. doi:10.1358/dot.2018.54.2.2760765

Hunt, R., Quigley, E., Abbas, Z., Eliakim, A., Emmanuel, A., Goh, K.-L., . . . Review, T. (2014). Coping With Common Gastrointestinal Symptoms in the Community: A Global Perspective on Heartburn, Constipation, Bloating, and Abdominal Pain/Discomfort May 2013. *J Clin Gastroenterol, 48*(7). Retrieved from https://journals.lww.com/jcge/Fulltext/2014/08000/Coping_With_Common_Gastrointestinal_Symptoms_in.4.aspx

IDSA/ACG/ASGE/AGA/NASPGHAN. (2013). Current Consensus Guidance on Donor Screening and Stool Testing for FMT. Retrieved from https://www.naspghan.org/files/documents/Joint_Scty_Signon_FDA%20FMT_final%207.15.13%20(1).pdf

Johnston, R. (2020). An overview of the innate immune system. Retrieved from https://www.uptodate.com/contents/an-overview-of-the-innate-immune-system?search=dysbiosis&source=search_result&selectedTitle=1~20&usage_type=default&display_rank=1

Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L., & Gordon, J. I. (2011). Human nutrition, the gut microbiome and the immune system. *Nature, 474*(7351), 327-336. doi:10.1038/nature10213

Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., . . . Wu, G. (2015). Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. *Gastroenterology, 149*(1), 223-237. doi:10.1053/j.gastro.2015.05.008

Kim, K. O., & Gluck, M. (2019). Fecal Microbiota Transplantation: An Update on Clinical Practice. *Clin Endosc, 52*(2), 137-143. doi:10.5946/ce.2019.009

Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., . . . Hawthorne, A. B. (2019). British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut, 68*(Suppl 3), s1. doi:10.1136/gutjnl-2019-318484

Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006). Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell, 124*(4), 837-848. doi:10.1016/j.cell.2006.02.017

Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006). Microbial ecology: human gut microbes associated with obesity. *Nature, 444*(7122), 1022-1023. doi:10.1038/4441022a

Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018). ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Official journal of the American College of Gastroenterology | ACG, 113*(4). Retrieved from https://journals.lww.com/ajg/Fulltext/2018/04000/ACG_Clinical_Guideline_Management_of_Crohn_s.10.aspx

Lo Presti, A., Zorzi, F., Del Chierico, F., Altomare, A., Cocca, S., Avola, A., . . . Guarino, M. P. L. (2019). Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. *Front Microbiol, 10*, 1655. doi:10.3389/fmicb.2019.01655

Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012). Diversity, stability and resilience of the human gut microbiota. *Nature, 489*(7415), 220-230. doi:10.1038/nature11550 Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., . . . Stoker, J. (2018). ECCOESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. *Journal of Crohn's and Colitis, 13*(2), 144-164K. doi:10.1093/ecco-jcc/jjy113

Malham, M., Lilje, B., Houen, G., Winther, K., Andersen, P. S., & Jakobsen, C. (2019). The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease. *Scand J Gastroenterol*, 1-7. doi:10.1080/00365521.2019.1644368

Michail, S., Nicholson, M., Kahn, S., & Kellermayer, R. (2020). Addendum for: Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr, 70*(3). Retrieved from https://journals.lww.com/jpgn/Fulltext/2020/03000/Addendum_for_Fecal_Microbiota_Transplantation_for.27.aspx

Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., . . . Williams, H. R. T. (2018). The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British

Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. *Gut, 67*(11), 1920. doi:10.1136/gutjnl-2018-316818

Myneedu, K., Deoker, A., Schmulson, M. J., & Bashashati, M. (2019). Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis. *United European Gastroenterol J, 7*(8), 1033-1041. doi:10.1177/2050640619866990

NICE. (2017). Irritable bowel syndrome in adults: diagnosis and management. Retrieved from https://www.nice.org.uk/guidance/cg61/chapter/1-Recommendations#diagnosis-of-ibs

Pang, T., Leach, S. T., Katz, T., Day, A. S., & Ooi, C. Y. (2014). Fecal Biomarkers of Intestinal Health and Disease in Children. *Front Pediatr, 2*. doi:10.3389/fped.2014.00006

Parada Venegas, D., De la Fuente, M. K., Landskron, G., Gonzalez, M. J., Quera, R., Dijkstra, G., . . . Hermoso, M. A. (2019). Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. *Front Immunol, 10*, 277. doi:10.3389/fimmu.2019.00277

Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. *Official journal of the American College of Gastroenterology | ACG, 115*(2). Retrieved from https://journals.lww.com/ajg/Fulltext/2020/02000/ACG_Clinical_Guideline Small_Intestinal_Bacterial.9.aspx

Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., . . . Ehrlich, S. D. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. *Nature, 464*(7285), 59-65. doi:10.1038/nature08821

Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., . . . Kristiansen, K. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature, 490*(7418), 55-60. doi:10.1038/nature11450 Raby, B. (2020). Tools for genetics and genomics: Polymerase chain reaction.

Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019). ACG Clinical Guideline: Ulcerative Colitis in Adults. *Official journal of the American College of Gastroenterology | ACG, 114*(3). Retrieved from https://journals.lww.com/ajg/Fulltext/2019/03000/ACG_Clinical_Guideline Ulcerative_Colitis_in.10.aspx

Simren, M., Barbara, G., Flint, H. J., Spiegel, B. M., Spiller, R. C., Vanner, S., . . . Zoetendal, E. G. (2013). Intestinal microbiota in functional bowel disorders: a Rome foundation report. *Gut, 62*(1), 159176. doi:10.1136/gutjnl-2012-302167

Snapper, S., & Abraham, C. (2020). Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease - UpToDate. Retrieved from https://www.uptodate.com/contents/immune-and-microbial-mechanisms-in-the-pathogenesisof-inflammatory-bowel-disease?source=see_link

Vaughn, B. P., Rank, K. M., & Khoruts, A. (2018). Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease. *Clin Gastroenterol Hepatol*. doi:10.1016/j.cgh.2018.07.026

Viome. (2019a, 03/28/2019). Demo Two. Retrieved from https://www.viome.com/storage/app/media/pdf/ViomeResults_BennySmalls.pdf

Viome. (2019b). Recommendations. Retrieved from https://www.viome.com/storage/app/media/pdf/ViomeRecommendations_BennySmalls.pdf

Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., . . . Krajmalnik-Brown, R. (2009). Human gut microbiota in obesity and after gastric bypass. *Proc Natl Acad Sci U S A, 106*(7), 23652370. doi:10.1073/pnas.0812600106

Zhernakova, A., Kurilshikov, A., Bonder, M. J., Tigchelaar, E. F., Schirmer, M., Vatanen, T., . . . Fu, J. (2016). Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science, 352*(6285), 565-569. doi:10.1126/science.aad3369

Zoetendal, E. G., Akkermans, A. D., & De Vos, W. M. (1998). Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. *Appl Environ Microbiol, 64*(10), 3854-3859. Retrieved from http://dx.doi.org/

IX.   Revision History

Revision Date	Summary of Changes
06-01-2021	Initial presentation